Axsome Therapeutics (AXSM) Common Equity (2015 - 2026)

Axsome Therapeutics' Common Equity history runs 12 years deep, the most recent figure standing at $54.6 million for Q1 2026.

• In Q1 2026, Common Equity rose 2.6% year-over-year to $54.6 million; the TTM figure through Mar 2026 stood at $54.6 million (up 2.6% YoY), while the FY2025 annual figure was $88.3 million, up 54.86% from the prior year.
• Common Equity came in at $54.6 million for Q1 2026 at Axsome Therapeutics, down from $88.3 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $278.8 million in Q2 2023 to a low of $14.7 million in Q1 2022.
• A 5-year average of $111.0 million and a median of $92.9 million in 2024 frame the typical range for Common Equity.
• Across the five-year window, Common Equity plunged 84.74% in 2022 and surged 1734.36% in 2023, its largest moves.
• Axsome Therapeutics' Common Equity stood at $109.6 million in 2022, then jumped by 74.32% to $191.0 million in 2023, then tumbled by 70.15% to $57.0 million in 2024, then jumped by 54.86% to $88.3 million in 2025, then slumped by 38.18% to $54.6 million in 2026.
• According to Business Quant data, Common Equity over the past three periods registered $54.6 million, $88.3 million, and $73.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison